Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2018 | ENESTop: deep molecular response in CML can be translated into treatment-free remission

Timothy Hughes • 14 Jun 2018

EHA 2018

Chronic Myeloid Leukemia Dasatinib Imatinib Nilotinib

ENESTcmr ENESTop

Timothy Hughes, MD, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an overview of the follow-up study of ENESTcmr. The ENESTop trial (NCT01698905) was designed to address whether deep molecular response in chronic myeloid leukemia (CML) could be translated into treatment-free remission (TFR). Over 50% of patients who started on imatinib and had switched to nilotinib remained in TFR. This suggests that switching a patient onto a diffeent tyrosine kinase inhibitor, in order to achieve a deaper response, will eventually translate into acheiving higher rates of TFR. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.